August 1, 2008
Abbott Laboratories on Wednesday agreed to pay between $10 million and $27.5 million to settle an antitrust lawsuit filed by HIV/AIDS advocates and other drug companies over an increase in the price of the company's antiretroviral drug Norvir, the AP/International Herald Tribune reports (AP/International Herald Tribune, 7/31).
Abbott in December 2003 quadrupled the per-patient wholesale price of Norvir, which is known generically as ritonavir. Norvir primarily is used as a booster for other protease inhibitors. Abbott exempted Medicaid, Medicare and state AIDS Drug Assistance Programs from the price increase and announced it would expand its patient assistance program. The cost of Norvir increased from $51.30 for 30 100-milligram capsules to $257.10 for 30 100-mg capsules, or by $5,000 more annually. In a suit filed in October 2007, GlaxoSmithKline and several pharmacy chains -- Safeway, Walgreen, Kroger, Supervalu's New Albertson's and American Sales -- also alleged that Abbott "unlawfully extended its monopoly position as the sole provider of Norvir" by increasing the drug's price (Kaiser Daily HIV/AIDS Report, 11/12/07).
The settlement will need to be approved by a federal judge in Oakland, Calif., where the suit was scheduled to go to trial next month, the AP/Herald Tribune reports. In addition, the final amount of the payout depends on an appeals court ruling of three legal questions, Abbott spokesperson Melissa Brotz said. Attorneys for the plaintiffs did not return calls for comment.
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2008 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.